Last updated: February 20, 2026
Who Are the Top Manufacturers of Loteprednol Etabonate?
Loteprednol etabonate is a corticosteroid used primarily for allergic conjunctivitis, postoperative inflammation, and other ocular inflammations. Multiple pharmaceutical companies produce this compound, often through licensing agreements and generic manufacturing.
Main Market Players
| Company |
Country |
Production Capacity |
Drug Forms |
Notable Markets |
| Bausch + Lomb |
USA |
High |
Ophthalmic suspension and gel |
North America, Europe |
| Sun Pharmaceutical |
India |
Moderate |
Ophthalmic suspension |
Asia, emerging markets |
| Sandoz (Novartis) |
Switzerland |
High |
Ophthalmic suspension |
Global |
| Amneal Pharmaceuticals |
USA |
Moderate |
Ophthalmic suspension |
US, Canada |
| TEVA Pharmaceuticals |
Israel |
High |
Ophthalmic suspension |
Global |
Licensing and Patent Status
- Patent Expiry: The original patent expired around 2003 in the U.S. [1].
- Generic Availability: Numerous generics produced globally; Sandoz, Teva, and Amneal dominate the market.
- Licensing Agreements: Some companies, like Bausch + Lomb, originally developed proprietary formulations, whereas others acquire licenses from patent holders.
Regulatory Approvals
- Approved by the U.S. Food and Drug Administration (FDA) since 2003.
- Approved in the European Medicines Agency (EMA) jurisdictions.
- Other regulators in Asia and Latin America have approved generic versions under local regulations.
Production and Supply Chain Considerations
- Key manufacturing facilities are based in the U.S., India, and Europe.
- Supply constraints may arise from formulation complexity and raw material sourcing.
- Regulatory compliance (GMP standards) is critical; most suppliers adhere to internationally recognized GMP standards.
Market Dynamics
- Growing prevalence of ocular inflammatory conditions drives demand.
- Patent expiration led to increased entry of generics.
- Supply chain disruptions can impact availability, especially during the COVID-19 pandemic.
Summary
Multiple pharmaceutical companies manufacture loteprednol etabonate, mainly through generic formulations. Leading suppliers include Bausch + Lomb, Sun Pharma, Sandoz, Amneal, and Teva. The active pharmaceutical ingredient (API) is produced mainly in the U.S., India, and Europe, with globally distributed finished products. The market is characterized by increased generic competition following patent expiry and consistent regulatory oversight.
Key Takeaways
- The patent for loteprednol etabonate expired around 2003, increasing generic production.
- Top suppliers are Bausch + Lomb, Sandoz, Teva, Sun Pharma, and Amneal.
- Market growth is driven by rising ocular inflammation cases; supply chain stability depends on manufacturing compliance.
- The drug is approved in major regions, with generics available worldwide.
- Supply constraints can affect pricing and availability, especially in emerging markets.
FAQs
1. When did patent protection for loteprednol etabonate expire?
Patent protection expired around 2003 in the United States.[1]
2. Who currently supplies generics of loteprednol etabonate?
Sandoz, Teva, Amneal, and others manufacture generic versions globally.
3. What formulations of the drug are available?
Primarily ophthalmic suspension and gel.
4. Are there regional differences in supplier availability?
Yes; while global brands are available worldwide, regional distribution varies based on regulatory approvals and manufacturing licenses.
5. What factors influence the supply chain stability for loteprednol etabonate?
Regulatory compliance, raw material sourcing, production capacity, and manufacturing disruptions.
References
[1] U.S. Patent and Trademark Office. (2003). Patent expiration date for loteprednol etabonate.
